Results 21 to 30 of about 30,070 (260)
Morphology of myeloproliferative neoplasms
International Journal of Laboratory Hematology, 2023 AbstractMyeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia‐negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre‐fibrotic myelofibrosis and primary myelofibrosis (PMF).
Zi Yun Ng +3 more
openaire +2 more sources
Update in the myeloproliferative neoplasms [PDF]
Clinical Medicine, 2014 The differential diagnosis of haematological abnormalities, such as leucocytosis, erythocytosis, thrombocytosis or indeed anaemia, is wide and disarming. Here we report on significant updates in the differential diagnosis of erythrocyosis and thrombocytosis presenting a simplified schema for the clinician.
Harrison, Claire N, McMullin, Mary F
openaire +3 more sources
Myeloproliferative Neoplasms [PDF]
JAMA Oncology, 2015 Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) constitute the BCR-ABL1-negative myeloproliferative neoplasms and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; respective frequencies of these mutations are ...
Ayalew, Tefferi, Animesh, Pardanani
openaire +2 more sources
Aetiology of Myeloproliferative Neoplasms [PDF]
Cancers, 2020 Myeloproliferative neoplasms (MPNs) have estimated annual incidence rates for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis of 0.84, 1.03, and 0.47 per 100,000. Prevalence is much higher, particularly for PV and ET, as mortality rates are relatively low.
Mary Frances McMullin +1 more
openaire +4 more sources
Genetics of Myeloproliferative Neoplasms
Hematology/Oncology Clinics of North America, 2021 Myeloproliferative neoplasms are hematopoietic stem cell disorders based on somatic mutations in JAK2, calreticulin, or MPL activating JAK-STAT signaling. Modern sequencing efforts have revealed the genomic landscape of myeloproliferative neoplasms with additional genetic alterations mainly in epigenetic modifiers and splicing factors.
Jakub, Szybinski, Sara C, Meyer
openaire +2 more sources
Haematologica, 2012 We investigated 15,542 patients with suspected BCR-ABL1- negative myeloproliferative or myelodysplastic/myeloproliferative neoplasm (including 359 chronic myelomonocytic leukemia) by a molecular marker set.
Susanne Schnittger +9 more
doaj +1 more source
Unbalanced rearrangement, der(9;18)(p10;q10) in a patient with myeloproliferative neoplasm. Case 0001M. [PDF]
, 2011 Case report of a translocation : Unbalanced rearrangement, der(9;18)(p10;q10) in a patient with myeloproliferative neoplasm. Case 0001M.
Reddy, KS
core +1 more source
Epigenetics in Myeloproliferative Neoplasms [PDF]
Journal of Cellular and Molecular Medicine, 2017 AbstractA decade on from the description of JAK2 V617F, the MPNs are circumscribed by an increasingly intricate landscape. There is now evidence that they are likely the result of combined genetic dysregulation, with several mutated genes involved in the regulation of epigenetic mechanisms. Epigenetic changes are not due to a change in the DNA sequence
Suzanne McPherson +2 more
openaire +3 more sources
A CASE OF HEADACHE TURNING INTO MYELOPROLIFERATIVE NEOPLASM-A CASE REPORT
, 2023 <p>Headache is an important clinical symptom commonly encountered by practising physicians. Thorough history and physical examination is a must for arriving at differentials of headache.
Sreeraj H.
core +1 more source
Molecular Genetics & Genomic Medicine, 2022 The JAK2 gene encodes for a non‐receptor tyrosine kinase that plays a key role in the JAK/STAT signaling transfer pathway. Genetic polymorphisms of this gene have been indicated to be associated with myeloproliferative neoplasm‐associated thrombosis in ...
Nguyen Thy Ngoc +3 more
doaj +1 more source